Management

Alfred Slanetz, Ph.D.

President and Chief Executive Officer

 

Dr. Slanetz joined Genetix as President and CEO in early 2007.  During a 20-year career in biotechnology and interest in gene therapy, Dr. Slanetz served 5 years on the Executive Committee and as Vice President of Business Development for the French gene therapy company Transgene.  At Transgene he was responsible for worldwide business development, including an $88 million licensing deal with Schering-Plough on adenoviral vectors and p53 and a 10% equity deal with Human Genome Sciences at the valuation of the Transgene IPO, in addition to numerous gene, technology and intellectual property transactions in the U.S., Europe and Japan.  Dr. Slanetz was instrumental in establishing Transgene’s US subsidiary, and in the $100 million IPO on NASDAQ and EuroNext, one of the most successful biotechnology IPOs of the 1990s.  Prior to Transgene, Dr. Slanetz was Head of New Product Planning at Genentech.  He was instrumental in developing Genentech’s Long Range Strategic Plan and Genentech’s first Oncology business plan, leading commercial forecasts/positioning of products in the pipeline and advising senior management on development decisions.  He was a member of the core development teams for Herceptin (Oncology), Avastin (Oncology), Lucentis (Opthamology), and Xolair (Asthma).  He was a key member of the negotiating team for in-licensing Rituxan (Oncology).    Dr. Slanetz received his Ph.D. in Immunobiology from Yale University, where he created the first soluble T cell receptor, studying affinity, kinetics and T cell recognition.  He received his M.S. in Biomedical Engineering from Brown University and his B.A. in Biology from Hamilton College.

 

 

Ronald C. Dorazio, M.D.

Founder and Vice President

 

As a Founder of GENETIX, Dr. Dorazio established the business by identifying key core gene therapy technology, assembling world leaders as scientific founders and advisors, licensing the intellectual property portfolio from Columbia University and launching the first corporate partnership with Rhone-Poulenc Rorer/Gencell, initiating the Company's first clinical trials. Prior to this, Dr. Dorazio was Founder and Vice President of Lifecodes Corporation, the first commercial laboratory to adapt molecular biology to forensic and paternity testing, raising over $12M in equity financing while establishing Lifecodes as the leader in this field. Lifecodes was sold to Quantum Chemical Corporation in 1987. Dr. Dorazio has a B.S. from the University of Notre Dame and an M.D. from New York Medical College. He is Board-Certified in Internal Medicine and completed a Hematology/Oncology Fellowship at the Memorial Sloan-Kettering Cancer Center.

 

Philippe Leboulch, Ph.D.

Founder & Chair of SAB

 

Dr. Leboulch is Assistant Professor of Medicine at Harvard Medical School in the Hematology/Oncology Division at the Brigham and Women's Hospital in Boston, and Research Scientist in the Harvard/MIT Division of Health Sciences and Technology at MIT. Dr. Leboulch is a scientific founder of Innogene Corporation, a gene therapy company that merged with GENETIX Pharmaceuticals in 1996. He is an expert in the fields of transcriptional regulation of erythroid-specific genes and of retrovirus-mediated gene transfer into hematopoietic stem cells. Dr. Leboulch is a member of the Scientific Committee on Viral Gene Therapy Vectors, The American Society of Gene Therapy.